Jasper Dijkstra

VenGen's investment strategy focuses on pre-seed stage ventures. They look for technologies that represent significant breakthroughs primarily in life sciences in addition to therapeutics, diagnostics, medical devices and platform technologies. They also consider ideas that have initial proof of concept such as validation via publication in peer-reviewed journals, protection through patent applications or awards of competitive grants. Among VenGen's other investment criteria are technologies or products with substantial market value which meet an unmet need and personal fit between the entrepreneur and the firm's founders. The firm provides various levels of funding. When the business concept, intellectual property, scientific basis and market potential are deemed promising, they provide an investment of EUR 10 thousand combined with entrepreneurial coaching (VenGen Support). Another stage of investment is when the business plan is defined, the spin-out process finalized and investors have been identified. At this point, VenGen invests up to EUR 50 thousand (VenGen Accell). VenGen is an active, hands-on partner. They provide business expertise and management experience in addition to initial funding. They are committed to their portfolio firm's by playing an active role. They draw on their wide network of specialized business and industry partners for the benefit of the entrepreneurs. They organize meetings with their advisory board members to discuss strategic developments and planning. VenGen also considers spin-out opportunities which are directly initiated by technology transfer officials associated with research departments of universities and life science institutes.

Functions as a College/University

Develops and manufactures diagnostic devices